In melanoma, acquired resistance to vemurafenib is a common result from MEK-ERK signaling reactivation achieved by diverse genetic mechanisms, including gain-of-function mutations in NRAS and KRAS, mutant BRAF amplification or MAP2K1 mutation [50,51,52]. This evidence concerns the gene MAP2K7 and melanoma.